Amphastar Pharmaceuticals, Inc. (AMPH) Stock

Amphastar Pharmaceuticals, Inc., headquartered in Rancho Cucamonga, California, is a prominent bio-pharmaceutical company engaged in the development, manufacturing, marketing, and sale of a diverse range of generic and proprietary injectable, inhalation, and intranasal products. Operating through two primary segments, Finished Pharmaceutical Products and API, Amphastar serves markets in the United States, China, and France with a robust portfolio of essential healthcare solutions.

The company offers a variety of critical medications including Primatene Mist, an over-the-counter epinephrine inhalation product for temporary relief of mild asthma symptoms; Enoxaparin, a low molecular weight heparin used to prevent and treat deep vein thrombosis; Naloxone for opioid overdose reversal; and Glucagon emergency kits for severe hypoglycemia. Additionally, Amphastar provides essential diagnostic and therapeutic products such as Cortrosyn for adrenal insufficiency screening, and Epinephrine injections for allergic reactions.

Amphastar's product lineup also includes specialty medications like Amphadase, a hyaluronidase injection that aids in dispersing other injected drugs, and lidocaine jelly and solution for anesthetic applications in various medical procedures. The company serves a wide range of healthcare facilities including hospitals, clinics, doctors' offices, and alternate care sites.

Founded in 1996, Amphastar Pharmaceuticals has established itself as a leader in the pharmaceutical industry, committed to innovation and quality in drug development. With a focus on meeting critical medical needs, Amphastar continues to expand its portfolio and global presence to better serve healthcare providers and patients worldwide.